The surprising thing I believe now after coming back as CEO of YC: The size of your round doesn’t matter. Having 70 mo runway gives you a lot of shots but it doesn’t get you product market fit. The thing that matters: you must be a great builder solving a real problem.

The N-of-1 Longevity Messiah Bryan Johnson /dd in the Y Combinator house hosted by Garry Tan

The Bryan Johnson /dd Blueprint algorithm for longevity tells you what to think and what to do and you must obey under threat of unspecified punishment. Sounds a lot like marriage but instead of “Don’t Die” it’s “Drop Dead”

Asked about irony in life, Bryan Johnson /dd responded right on cue: “I’m going to die getting hit by a bus.”

TODAY! 📆 Come meet fellow #longevity enthusiasts at the first Vitalism meetup in SF! 🧬 "Intro to Vitalism" talk by Adam Gries, speed-networking & lightning talks ⚡ 📍55 Grace St (Cellsius Labs) @ 17:30

A VC-funded biotech platform startup backed by the biggest names in the business and led by seasoned management vaporized $213M in 10 months. I’ve seen rare disease parents discover or create medicines and treat their kids in that same amount of time for 0.1-1% of the cost.

.Ethan Perlstein bio/acc is right. One order of magnitude down, one, I've seen a researcher take a solid eight figures from the NIH over the past six years to "find a drug for #SYNGAP1" & I've seen ZERO drugs. Meanwhile SynGAP Research Fund (SRF) has invested ~$1m & we've found two. #FundPatientAdvocates

It's not just patients who wants drugs to come to market faster and cheaper. Investors are burning their capital on traditional biotech models. We need fresh thinking. DeSci offers a new path -- one that is more transparent and capital efficient, because it's led by patients.

I’ve said it a million times and I’ll say it again: “rare diseases” is terrible marketing and a big reason why no one cares about rare expect for those who are personally affected. “Rare” diseases was supposed to be catchier than “orphan” diseases, which has to be the worst

Ethan Perlstein bio/acc Northern light diseases (It captures the rare common connection, but subtly, and gives the sense that it’s a rare occurrence that lights the way to hope). Diamond diseases, Phoenix diseases, Unicorn diseases

Founder Mode: paulgraham.com/foundermode.ht…

This paper on thromboinflammation is everywhere this week. Unfortunately nobody commenting on it seems to have read it! I have, and it definitely doesn't say what commentators are suggesting. 🧵nature.com/articles/s4158…

Founder Mode will be the catch phrase of Q4

This was one of the best talks I’ve ever heard - thx to Paul Graham for capturing the key message. This is an absolute must-read for founders. Don’t let anyone - VCs or otherwise - convince you to move out of “founder mode”. paulgraham.com/foundermode.ht…

"Till now most people even in Silicon Valley have implicitly assumed that scaling a startup meant switching to manager mode. But we can infer the existence of another mode from the dismay of founders who've tried it, and the success of their attempts to escape from it."

In Warsaw the rest of the week for the PACS2 Research Foundation conference!

Rare disease parents get founder mode.